Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1702-1708

  Kwaan, H C ^a,c   Wang, J ^a   Svoboda, K ^a   Declerck, P J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Plasminogen activator inhibitor 1; UPA receptor

Indexed keywords

CAMPTOTHECIN; ETOPOSIDE; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR;

APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CELL LINE; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; DNA FRAGMENTATION; ETOPOSIDE; HL-60 CELLS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 0034014726     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alizadeh H, Ma D, Berman M, Bellingham D, Comerford SA, Gething MH, Sambrook JF and Niederkorn JY (1995) Tissue type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 14: 449-458
2. Andreasen PA, Kjoller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
3. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusening NE, Carmeliet P, Tollen D and Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928
4. Bashar H, Urano T, Pietrazek MH, Hata M, Suzuki K, Kawabe, K, Takada Y and Takada A (1994) Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int 52: 4-8
5. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL and Testuz J (1990) Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87: 6939-6943
6. Casslen B, Bossmar T, Lecander I and Astedt B (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30: 1302-1309
7. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
8. Debrock S and Declerck PJ (1997) Neutralization of plasminogen activator inhihitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1337: 257-266
9. Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571
10. Egelund R, Schousboe SL, Sottrup-Jensen L. Rodenburg KW and Andreasen PA (1997) Type-1 plasminogen-activator inhibitor: conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 248: 775-785
11. Fockens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F and Klijn JG (1993) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
12. Gils A, Knockaert I and Declerck PJ (1996) Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochem 35: 7474-7481
13. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
14. Hofmann R, Lehmer A, Buresch M, Hartung R and Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487-492
15. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N. Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
16. Kanse SM, Kost C, Wilhelm OG, Andreasen PA and Preissner KT (1996) The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 224: 344-353
17. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L and Andreasen PA (1997) Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232: 420-429
18. Kobayashi H, Fujishiro S and Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type I on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548
19. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F and Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409
20. Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metast Res 11: 291-311
21. Levenson AS, Kwaan HC, Svoboda KM, Weiss IM, Sakurai S and Jordan VC (1998) Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 78: 88-95
22. Nekarda H, Siewert JR, Schmitt M and Ulm K (1994) Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117
23. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K and Brunner N (1994) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123
24. Sancho E, Declerck PJ, Price NC, Kelly SM and Booth NA (1995) Conformational studies on plasminogen activator inhibitor (PAI-I) in active, latent, substrate, and cleaved forms. Biochemistry 34: 1064-1069
25. Sier CFM, Vloedgraven HJM, Ganesh S, Griffion G, Quax PHA, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJH, Lamers CBHW and Verspaget H (1994) Inactive urokinase and increased levels of inhibitor type I in colorectal cancer liver metastasis. Gastroenterology 10: 1449-1456
26. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S and Kwaan HC (1995) Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96: 2593-2600
27. Stefansson S and Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383: 441-443
28. Sugiura Y, Ma L, Sun B, Shimada H. Laug WE, Seeger RC and DeClerck Y (1999) The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res 59: 1327-1336
29. Verhamme I, Kvassman J, Day D, Debrock S, Vleufels N, Declerck PJ and Shore JD (1999) Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 274: 17511-17517
30. Vleugels N, Gils A, Mannaerts S, Knockaert I and Declerck PJ (1998) Evaluation of the mechanism of inactivation of plasminogen activator-1 by monoclonal antibodies using a stable variant. Fibrinolysis Protelysis 12: 277-282
31. Waltz DA, Natkin LR, Fujita RM, Wei Y and Chapman HA (1997) Plasmin and plasminogen activator inhibitor type I promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100: 58-67
32. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S and Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388